ArticleFrontiers in immunology2026
The Sm29 antigen differentially shapes transcriptomic and regulatory landscapes across reactional forms of leprosy.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: It is documented that Methods: Peripheral blood mononuclear cells (PBMCs) were cultured and stimulated with sonicated Results: The Sm29 antigen was able to modulate immune response pathways in leprosy, with this response being more pronounced in the reactional forms of the disease, especially in RR. Interestingly, when compared to sonicated Conclusion: Leprosy proves to be an efficient model for investigating products capable of regulating the host inflammatory response. Here, we open perspectives for new insights in the use of immunobiological, expanding attention to this field that might help management of leprosy patients, especially in reactional episodes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.